On April 16, the first batch of influenza vaccines (split virion, inactivated, quadrivalent) developed by Changchun Institute of Biological Products Co Ltd (CCIBP), a subsidiary of CNBG, Sinopharm Group, received approval for their release and entered the market.

The vaccine has been developed based on the influenza strains recommended by the World Health Organization (WHO) for the 2025-26 seasonal flu vaccine. Its marketing will play an important role in influenza prevention and control in China, further meeting public vaccination demand.

The influenza vaccine (split virion, inactivated, quadrivalent) developed by CCIBP [Photo/sinopharm.com] 

As a common acute respiratory infectious disease, influenza spreads rapidly and can cause seasonal outbreaks, particularly in crowded settings such as schools and nursing homes. Influenza vaccination remains one of the most cost-effective measures to prevent and control influenza and its complications.

The WHO annually forecasts circulating influenza strains in both the Northern and Southern Hemispheres. In February this year, the WHO officially announced the recommended strains for the 2025-26 Northern Hemisphere seasonal influenza vaccine to guide global vaccine R&D and production. 

As China’s pioneering influenza vaccine R&D and production base, CCIBP has consistently maintained stringent quality standards to ensure a reliable vaccine supply. Its influenza vaccines have been marketed domestically for 23 consecutive years, featuring preservative-free formulation with stable quality, proven safety and efficacy. 

In October 2023, CCIBP’s influenza vaccine (split virion, inactivated, trivalent) was prequalified by the WHO, contributing China’s strength to global healthcare. 

Going forward, CCIBP will remain steadfast in its corporate mission of “all for health, health for all”. It will focus on the R&D and production of vaccines targeting prevalent strains and will also rigorously uphold quality standards to ensure a stable supply of influenza vaccines. As a central State-owned enterprise, Sinopharm will continue to play a pivotal role in supporting national influenza prevention and control efforts.